Management of H. pylori-Associated Gastritis with Intestinal Metaplasia in a 77-Year-Old Male
This patient requires immediate H. pylori eradication therapy followed by endoscopic surveillance every 3 years due to the presence of intestinal metaplasia in the antrum. 1
Immediate Management: H. pylori Eradication
H. pylori eradication is essential and serves as the cornerstone of both primary and secondary gastric cancer prevention 1. The evidence is unequivocal that eradication reduces gastric cancer risk 2, and this benefit persists even after preneoplastic conditions like intestinal metaplasia have developed, though the protective effect is greater when treatment occurs before these changes arise 2.
Treatment Approach:
- First-line therapy: Bismuth-containing quadruple therapy is recommended in regions of high clarithromycin resistance 2
- Alternative regimens: Sequential therapy or non-bismuth quadruple therapy if bismuth preparations are unavailable 2
- Confirmation of eradication: Perform urea breath test (UBT) or validated monoclonal stool antigen test at least 4 weeks after completing treatment 2
- Do NOT use serology for post-treatment confirmation 2
- Endoscopic confirmation with biopsy is appropriate given the need for surveillance endoscopy
Risk Stratification and Surveillance Strategy
This patient has moderate-to-high risk features warranting ongoing surveillance:
Risk Factors Present:
- Intestinal metaplasia in the antrum (a preneoplastic lesion)
- Active H. pylori infection with moderate inflammation
- Advanced age (77 years)
Surveillance Protocol:
Endoscopic surveillance every 3 years is recommended 1, 3. While some guidelines suggest surveillance may not be necessary for mild-to-moderate atrophy restricted to the antrum alone 3, the presence of intestinal metaplasia changes this calculus—IM represents a more advanced stage in the Correa cascade and warrants monitoring.
High-Quality Surveillance Endoscopy Should Include:
- High-definition white-light endoscopy with image enhancement (virtual chromoendoscopy) 1, 3
- Gastric mucosal cleansing prior to examination 1
- Systematic biopsy protocol: Minimum 5 biopsies with samples from antrum/incisura and corpus placed in separately labeled jars 1, 3
- Adequate inspection time with photodocumentation 1
- Targeted biopsies of any visually suspicious areas 1
Important Caveats and Clinical Considerations
Reversibility of Lesions:
The evidence shows that atrophy may be reversible in the corpus but not in the antrum after H. pylori eradication 2. There is uniform agreement that intestinal metaplasia is irreversible 2, though some recent data suggest potential improvement in select cases 4. Regardless, eradication prevents progression and reduces cancer risk even when IM persists 3, 5.
Histologic Subtyping Matters:
Work with your pathologist to document:
- Presence/absence of H. pylori after treatment
- Severity and extent of atrophy and metaplasia
- Histologic subtype of intestinal metaplasia (incomplete/complete type) if applicable 1
- Incomplete IM carries higher cancer risk and may warrant more intensive surveillance
When to Intensify Surveillance:
Consider shorter intervals than 3 years if:
- Family history of gastric cancer in first-degree relatives 1
- Incomplete (Type III) intestinal metaplasia is identified 3
- Multifocal or extensive IM develops 1
- Any dysplasia is detected on future biopsies (requires immediate high-quality endoscopic reassessment) 3
Age Considerations:
At 77 years, consider the patient's overall health status, life expectancy, and comorbidities when planning long-term surveillance. However, given no dysplasia is present and gastric cancer can develop over years, surveillance remains appropriate if the patient has reasonable life expectancy and functional status.
What NOT to Do:
- Do not rely on serology for H. pylori eradication confirmation 2
- Do not perform surveillance without confirming successful eradication first
- Do not obtain biopsies from antrum and corpus in the same jar—separate labeling is critical for staging 1, 3
- Do not discontinue surveillance after one negative follow-up endoscopy—IM requires ongoing monitoring 1